Genomic medicine has transitioned from research tool to clinical reality faster than most clinicians anticipated. The cost of whole genome sequencing has fallen from $3 billion (Human Genome Project, 2003) to under $200 (Illumina NovaSeq X, 2023) — a 10-million-fold cost reduction that has placed comprehensive genomic information at the threshold of clinical accessibility. While population-scale genomic screening remains in deployment planning stages, specific genomic applications are now established clinical practice: pharmacogenomics, hereditary cancer syndrome testing, somatic tumor profiling, and increasingly polygenic risk score assessment. Healthcare laboratories supporting genomic testing programs can source appropriate specimen collection supplies from our laboratory supplies section.
Pharmacogenomics: Actionable in Clinical Practice Now
Pharmacogenomics (PGx) — the study of how genetic variants in drug-metabolizing enzymes, transporters, and targets influence drug response — has reached clinical maturity for several high-impact drug-gene interactions. CPIC (Clinical Pharmacogenomics Implementation Consortium) guidelines provide prescribing recommendations for 50+ drug-gene pairs: CYP2C19 poor metabolizers (15% of patients) have significantly reduced clopidogrel efficacy — alternative antiplatelet therapy is recommended; CYP2D6 poor metabolizers (8% of patients) cannot convert codeine to morphine — codeine is contraindicated; TPMT/NUDT15 poor metabolizers cannot tolerate standard thiopurine (azathioprine, mercaptopurine) doses without severe myelosuppression; HLA-B*57:01 carriers have high risk of abacavir hypersensitivity syndrome — screening is FDA-mandated before abacavir initiation. PGx testing panels from Genomind, Myriad GeneSight, and Tempus are now covered by many commercial payers for psychiatry, oncology, and cardiology applications.
Hereditary Cancer Testing: The BRCA Era and Beyond
BRCA1/2 hereditary breast and ovarian cancer testing — validated since 1996 — has expanded to germline panel testing covering 50+ cancer predisposition genes (Lynch syndrome, CDH1/hereditary diffuse gastric cancer, STK11/Peutz-Jeghers, TP53/Li-Fraumeni, and many others) at declining cost through Myriad Genetics, Invitae, Ambry Genetics, and Color Health. NCCN guidelines now recommend germline panel testing for: all ovarian cancer patients; all pancreatic cancer patients; breast cancer patients under 50 or with Ashkenazi Jewish ancestry or other risk features; and prostate cancer patients with metastatic disease or family history. Cascade testing (testing family members after a positive index case) is the highest-yield application — identifying at-risk relatives who can benefit from enhanced screening and risk reduction.
